+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Rethinking therapeutic decisions for hepatitis B infection in Syria: insights into molecular monitoring



Rethinking therapeutic decisions for hepatitis B infection in Syria: insights into molecular monitoring



Journal of Infection in Developing Countries 6(10): 744-747



Hepatitis B virus patients are usually treated in Syria with alpha interferon and nucleos(t)ide analogues. Genotypic viral factors causing inadequate response or relapse following initial response are not routinely investigated. This study aimed to explore and discuss local therapeutic decisions from a molecular perspective. Fifty patients with hepatitis B from Syria were tested for HBV genotyping and drug-resistance mutations by DNA sequencing. All patients had genotype D, which is characterized by relatively low response to interferon-based therapy. Drug-resistant viral mutant variants were detected in one fifth of the enrolled patients, and distributed similarly in both nucleos(t)ide analogues-naïve and -treated patients. However, nucleos(t)ide analogues-based therapy was associated with the existence of more mutations and hence increased resistance. Investigating HBV genotypes and drug-resistance mutations to support treatment decisions is critically needed for efficient therapy and patients' survival.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 055544353

Download citation: RISBibTeXText

PMID: 23103897


Related references

Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection?. Hepatology 48(5): 1451-1459, 2008

Improving Therapeutic Decisions: Pharmacodynamic Monitoring as an Integral Part of Therapeutic Drug Monitoring. Therapeutic Drug Monitoring 41(2): 111-114, 2019

Improving therapeutic decisions: Pharmacodynamic monitoring as an integral part of Therapeutic Drug Monitoring. Therapeutic Drug Monitoring 2019, 2019

Know your enemy: translating insights about the molecular biology of hepatitis C virus into novel therapeutic approaches. Expert Review of Gastroenterology and Hepatology 4(1): 63-79, 2010

Alanine aminotransferase course, serum hepatitis B virus DNA, and liver stiffness measurement for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B. Hepatology Research 46(13): 1347-1357, 2016

Molecular therapeutic strategies in hepatitis B virus infection. Clinical Investigator. 72(10): 737-741, 1994

Routine therapeutic drug monitoring in patients on protease inhibitors Impact on therapeutic decisions?. AIDS 14(Supplement 4): S91-S92, 2000

Rethinking the pathogenesis of hepatitis B virus (HBV) infection. Journal of Medical Virology 87(12): 1989-1999, 2016

Rethinking hepatitis C viral kinetics: Insights into host-virus interactions in 'difficult-to-treat' groups and implications for novel treatment approaches. Journal of Hepatology 43(5): 748-750, 2005

Monitoring hepatitis C infection in a major Swedish nephrology unit and molecular resolution of a new case of nosocomial transmission. Journal of Medical Virology 82(2): 249-256, 2010

A comprehensive evaluation of rhythm monitoring strategies for the detection of atrial fibrillation recurrence: insights from 647 continuously monitored patients and implications for monitoring after therapeutic interventions. Circulation 126(7): 806-814, 2013

Decisions Decisions Decisions and how we make them -- insights from Psychological Science. 2012

Immunopathogenesis of hepatitis C virus infection and hepatic fibrosis: New insights into antifibrotic therapy in chronic hepatitis C. Hepatology Research 37(8): 579-595, 2007

Intensive temporal mapping of hepatitis C hypervariable region 1 quasispecies provides novel insights into hepatitis C virus evolution in chronic infection. Journal of General Virology 96(8): 2145-2156, 2015

Hepatitis C genotype and hepatitis G in hemodialysis patients from Syria The identification of two novel hepatitis C subtypes. Hepatology 24(4 PART 2): 149A, 1996